GRM5 and schizophrenia: These data highlight differential acute vs. chronic effects of CDPPB and support a growing number of evidence that mGluR5 PAMs have robust efficacy in a range of learning and memory in preclinical models of schizophrenia (Liu et al., 2008; Conn et al., 2009; Homayoun and Moghaddam, 2010).